The conversation around GLP-1 receptor agonists in recent years has been dominated, understandably, by what these medications can do for people who respond well to them. The results are genuinely remarkable, and the enthusiasm in both clinical circles and the general public reflects real outcomes in real patients. But enthusiasm for a drug class, however justified, should not obscure the clinical reality that no medication is right for everyone, and GLP-1 therapy is no exception.
A significant part of practicing responsible medicine is the evaluation that happens before a prescription is written. For GLP-1 medications, that evaluation involves a careful review of medical history, current conditions, concurrent medications, and patient-specific risk factors that may change the benefit-risk calculation entirely. Understanding what physicians are looking for during that evaluation, and why certain patient profiles call for caution or alternative approaches, is information that benefits both patients and the people who care about them.
The Absolute Contraindications
There are patient profiles for whom GLP-1 receptor agonists are contraindicated, meaning the risk is clear enough that the medication should not be used regardless of the potential benefit.
The most important is a personal or family history of medullary thyroid carcinoma (MTC). GLP-1 receptors are expressed in thyroid C-cells, and animal studies showed dose-dependent increases in thyroid C-cell tumors with GLP-1 receptor agonists. While the relevance of these animal findings to human risk has been debated, the regulatory position for most agents in this class is a contraindication in patients with a personal or family history of MTC. This applies regardless of how distant the family history is or how low the patient perceives their individual risk to be.
The second absolute contraindication is multiple endocrine neoplasia syndrome type 2 (MEN 2), a hereditary condition that significantly increases the risk of MTC. Patients who carry MEN 2 mutations or who have a confirmed diagnosis should not be prescribed GLP-1 receptor agonists.
Beyond these two, a prior serious hypersensitivity reaction to a GLP-1 agent constitutes a contraindication to that specific agent and warrants careful consideration before trying any related compound. These reactions are rare but real, and a documented history of one changes the clinical calculus entirely.
History of Pancreatitis: A Clinical Caution That Requires Judgment
A history of pancreatitis sits in a more nuanced category than a strict contraindication, but it is one of the factors I evaluate most carefully before prescribing GLP-1 therapy. There is a theoretical mechanism by which GLP-1 receptor agonists could affect pancreatic function, and while the largest clinical trials have not established a causal relationship between these medications and pancreatitis events at a population level, the picture in individual patients with a history of the condition is less clear.
Patients who have had a single episode of acute pancreatitis with a clearly identified and resolved cause, such as gallstones that have been surgically addressed, represent a different risk profile than patients with recurrent idiopathic pancreatitis or chronic pancreatitis. For the former, GLP-1 therapy may be appropriate with careful monitoring and an informed discussion of the theoretical risk. For the latter, I would want a strong clinical rationale and would consider alternatives first.
This is exactly the kind of nuanced conversation that a prescribing physician needs to have with each individual patient rather than applying a blanket rule. The history, the cause, the resolution, and the overall benefit-risk profile all factor into the decision.
Gastroparesis and Gastrointestinal Motility Disorders
GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action. This is one of the ways they promote satiety and reduce post-meal blood sugar spikes. For most patients, this effect is tolerable and contributes to the treatment benefit. For patients with existing gastroparesis, a condition characterized by already delayed gastric emptying, it can substantially worsen symptoms.
Gastroparesis causes nausea, vomiting, bloating, and unpredictable food absorption. Adding a medication that further slows gastric emptying to this picture can significantly impair quality of life and make blood sugar management more difficult rather than easier. Patients with a confirmed diagnosis of gastroparesis, or those with symptoms strongly suggestive of it, should be evaluated carefully before starting GLP-1 therapy, and the diagnosis should be communicated clearly to any prescribing physician.
This also has implications for how patients communicate their symptom experience during treatment. The nausea that commonly occurs in the first weeks of GLP-1 therapy is expected and typically resolves. Nausea that persists at higher intensity or that is accompanied by significant vomiting and early satiety beyond the adjustment period warrants assessment for whether an underlying motility issue is being unmasked rather than simply assuming it is a medication side effect to push through.
Kidney Function and Dehydration Risk
GLP-1 medications are associated with nausea and vomiting, particularly during dose escalation. In patients with impaired kidney function, the dehydration that can accompany these side effects carries a higher risk of acute kidney injury than in patients with normal renal function. This does not mean that patients with chronic kidney disease cannot take GLP-1 medications, but it does mean that the prescribing conversation should include explicit guidance on maintaining adequate hydration, recognizing the signs of dehydration, and knowing when to contact the prescribing physician.
For patients with severe kidney impairment, individual agents in this class have different data profiles, and the specific medication and dosing regimen need to be matched to the patient’s renal function. This is an area where the details of which drug is being prescribed matter considerably, and where a physician with specific expertise in this intersection of conditions adds real value.
Medication Interactions and Diabetic Considerations
Patients on insulin or insulin secretagogues who add a GLP-1 receptor agonist to their regimen face an increased risk of hypoglycemia. This is not a contraindication, but it is a clinical situation that requires active management. Insulin doses typically need to be reduced when GLP-1 therapy is initiated, and the reduction needs to be calibrated rather than guessed. Patients in this situation should have a clear plan for monitoring blood sugar more frequently during the transition and a specific threshold for when to contact their physician.
GLP-1 medications also slow gastric emptying, which can affect the absorption of oral medications taken at the same time. For medications where precise timing and absorption are clinically significant, such as certain oral hormones, anticoagulants, or medications with narrow therapeutic windows, the interaction between GLP-1-induced delayed gastric emptying and drug absorption is worth discussing with a pharmacist or prescribing physician before starting treatment.
Pregnancy, Breastfeeding, and Reproductive Considerations
GLP-1 receptor agonists should not be used during pregnancy. Animal reproductive studies have shown adverse effects at clinically relevant exposures, and the human safety data during pregnancy is insufficient to establish safety. Women of reproductive age who are prescribed GLP-1 medications should be counseled about this, and most clinical guidelines recommend discontinuing the medication at least two months before attempting conception, given the extended half-life of some agents in this class.
For patients who are breastfeeding, the data on excretion into breast milk is limited and insufficient to establish safety. Current guidance recommends against use during breastfeeding. These are not minor considerations, and a thorough prescribing conversation for women in reproductive years should address them explicitly rather than leaving them to be discovered after the fact.
What This Means for Patients Researching Their Options
The availability of detailed, physician-reviewed information about GLP-1 medications and who should or should not take them helps patients come to their appointments with a clearer picture of their own risk profile. A patient who already knows that their history of pancreatitis is something a physician will want to discuss in detail, or who understands that their gastroparesis symptoms are clinically relevant to the prescribing decision, is in a much stronger position to have a productive and complete conversation than one who walks in without that context.
Understanding the contraindications and cautions for any medication is not a reason to be discouraged about treatment. It is a reason to approach the clinical conversation with the specificity it deserves. For many patients who have concerns about their individual profile, the assessment will conclude that GLP-1 therapy is appropriate with monitoring and specific precautions. For others, the evaluation will point toward a different approach that is actually better suited to their situation.
The Evaluation Is Part of the Treatment
The clinical assessment before prescribing GLP-1 therapy is not an obstacle placed between patients and treatment. It is part of the treatment. A medication prescribed to the right patient at the right dose with appropriate monitoring produces substantially better outcomes than the same medication prescribed without that foundation.
Physicians who take the time to conduct a thorough pre-prescribing evaluation, who ask the questions that surface relevant history, and who have honest conversations about individual risk are doing the work that turns a powerful drug class into a safe and effective treatment for the specific person in front of them. Patients who come prepared to have that conversation, who know their history and can articulate it clearly, make that work easier and their own outcomes better.
Image Credit: Magnific
Dr. Humberto Fernandez Miro, MD, is a board-certified physician and medical contributor at WeightLossPills.com, where he specializes in obesity medicine, GLP-1 therapy, and metabolic health.
